|
⚲
|
| Keyboard |
| Decheng Capital Management IV Cayman LLC | |
|---|---|
| Firm | Decheng Capital LLC |
| Address | c/o Maples Corporate Services Limited Ugland House, PO Box 309 Grand Cayman, E9 KY1-1104 |
| Source |
| Associated Funds | Form D | Role | 2011 - 2026 | Raised | AUM |
|---|---|---|---|---|---|
| Decheng Capital LLC | |||||
| Decheng Capital Global Life Sciences Fund IV LP | 021-383255 | Promoter | of 650.0 M |
825.3 M | |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Aardvark Therapeutics Inc AARD
Common Stock
|
2025-02-14 | Conversion | 2,333,887 | ||
|
Aardvark Therapeutics Inc AARD
Common Stock
|
2025-02-14 | Buy | 625,000 | $16.00 | 10,000,000 |
|
Aardvark Therapeutics Inc AARD
Common Stock
|
2025-02-14 | Buy | 625,000 | $16.00 | 10,000,000 |
|
Aardvark Therapeutics Inc AARD
Common Stock
|
2025-02-14 | Conversion | 333,412 | ||
|
Aardvark Therapeutics Inc AARD
Series C Convertible Preferred Stock · derivative
|
2025-02-14 | Conversion | 19,777,363 | $0.00 | |
|
Aardvark Therapeutics Inc AARD
Series C Convertible Preferred Stock · derivative
|
2025-02-14 | Conversion | 2,825,337 | $0.00 | |
|
CG Oncology Inc CGON
Common Stock
|
2024-01-29 | Conversion | 3,628,198 | ||
|
CG Oncology Inc CGON
Common Stock
|
2024-01-29 | Buy | 400,000 | $19.00 | 7,600,000 |
|
CG Oncology Inc CGON
Series C Preferred Stock · derivative
|
2024-01-29 | Conversion | 8,644,891 | ||
|
CG Oncology Inc CGON
Series F Preferred Stock · derivative
|
2024-01-29 | Conversion | 4,402,320 | ||
|
CG Oncology Inc CGON
Series E Preferred Stock · derivative
|
2024-01-29 | Conversion | 21,547,685 |